@article{PATENT,
      recid = {9115},
      title = {Optimization of cancer treatment with irinotecan},
      number = {PATENT},
      month = {Oct},
      year = {2004},
      abstract = {Various embodiments of the invention include methods and  compositions for evaluating the risk of irinotecan toxicity  in a patient. In certain embodiments, the methods include  detecting a promoter polymorphism in one or both UGT1A1  genes of the patient. In particular embodiments the  promoter polymorphism is a single nucleotide polymorphism  and may be in linkage disequilibrium with a UGT1A1 (TA)n  repeat. The methods may include obtaining a nucleic acid  sample from the patient and detecting the presence or  absence of a promoter polymorphism. The promoter  polymorphism may be at nucleotide position -3440, -3401,  -3279, -3177, -3175, or -3156 from the UGT1A1 gene  transcriptional start site. The number of TA repeats can be  5, 6, 7, 8 more TA repeats. In particular embodiments, the  promoter polymorphism is a -3440C>A, -3401T>C, -3279G>T,  -3177C>G, -3175A>G, -3156G>A polymorphism or any  combination thereof. Moreover, in other embodiments,  identification of a guanine residue at position -3156  indicates the patient does not have a low level of UGT1A1  activity, and therefore, methods and compositions of the  invention concern this identification.},
      url = {http://knowledge.uchicago.edu/record/9115},
}